Capricor: I Rate It A Buy After Stress-Testing The Sell Thesis
Capricor Therapeutics, Inc. is rated a speculative Buy as it approaches a critical PDUFA date for its drug deramiocel. Recent data from the HOPE-3 trial has alleviated many concerns regarding the drug's efficacy and safety. However, the company still faces risks related to commercial disputes and market limitations.
- ▪Capricor is preparing for a PDUFA date on August 22 for its drug deramiocel.
- ▪Recent HOPE-3 trial data has addressed concerns about primary and cardiac endpoints.
- ▪The company faces ongoing risks from commercial disputes with NS Pharma and Nippon Shinyaku.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"Long Ideas","item":"https://seekingalpha.com/stock-ideas/long-ideas"},{"@type":"ListItem","position":4,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4911297-capricor-stock-rate-it-a-buy-after-stress-testing-the-sell-thesis"},"author":{"@type":"Person","name":"High Alpha…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
